Literature DB >> 10226896

Protective effects of Celsior in lung transplantation.

L Xiong1, J Legagneux, M Wassef, A Oubenaïssa, H Détruit, C Mouas, P Menasché.   

Abstract

BACKGROUND: Celsior is a new preservation solution for heart transplants that recently has been shown also to improve protection of pulmonary grafts. As these data were obtained in isolated lung preparations, we sought to perform further tests with an in vivo model of allogeneic lung transplantation.
METHODS: The left lungs of 41 rats were either transplanted immediately after harvest (controls) or flushed with and cold stored in Celsior or the blood-based Wallwork solution for 5 or 12 hours. Lungs were then reperfused for 30 minutes, after which ligation of the contralateral pulmonary artery and bronchus made the recipient rat exclusively dependent on the transplanted lung. Assessment of preservation was made on functional (blood gases, pulmonary hemodynamics) and structural (dry-to-weight ratio, light microscopy, myeloperoxidase [MPO] content) end points.
RESULTS: The protective effects of Celsior were primarily manifest, once the contralateral lung had been functionally excluded, as a better preservation of oxygen tensions in the 5-hour storage experiments (416 +/- 52 mm Hg vs 406 +/- 59 mm Hg in controls [p = NS] and vs 239 +/- 34 mm Hg in Wallwork [p < 0.05 vs the 2 other groups]) and a smaller increase in pulmonary vascular resistance in the 12-hour storage experiments (10.2 +/- 4.1 mm Hg/mL/minute vs 3.2 +/- 1.1 mm Hg/mL/minute in controls [p = NS] and vs 23.1 +/- 4.3 mm Hg/mL/minute in Wallwork [p < 0.02 vs Celsior, p < 0.002 vs controls]). Survival was also longer in the 12-hour preserved Celsior group. Other end points were not significantly different between the two preservative solutions.
CONCLUSION: These data support the efficacy of Celsior as a flush-out and storage solution for pulmonary grafts. Given its previously documented ability to adequately preserve heart transplants, Celsior might provide a unified "solution" to thoracic organ preservation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10226896     DOI: 10.1016/s1053-2498(98)00032-1

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  6 in total

1.  Hypothermic in situ perfusion of the porcine liver using Celsior or Ringer-lactate solution.

Authors:  S Dinant; H J Roseboom; M Levi; A K van Vliet; T M van Gulik
Journal:  Langenbecks Arch Surg       Date:  2008-03-20       Impact factor: 3.445

2.  Influence of the selected antioxidants on the stability of the Celsior solution used for perfusion and organ preservation purposes.

Authors:  Aneta Ostrózka-Cieślik; Barbara Dolińska; Florian Ryszka
Journal:  AAPS PharmSciTech       Date:  2009-04-21       Impact factor: 3.246

3.  Improved lung preservation relates to an increase in tubular myelin-associated surfactant protein A.

Authors:  Heinz Fehrenbach; Sebastian Tews; Antonia Fehrenbach; Matthias Ochs; Thorsten Wittwer; Thorsten Wahlers; Joachim Richter
Journal:  Respir Res       Date:  2005-06-21

4.  Donor lung preservation for transplantation-where do we go from here?

Authors:  Dirk Van Raemdonck; Jan Van Slambrouck; Laurens J Ceulemans
Journal:  J Thorac Dis       Date:  2022-09       Impact factor: 3.005

5.  Comparison of Celsior and Perfadex lung preservation solutions in rat lungs subjected to 6 and 12 hours of ischemia using an ex-vivo lung perfusion system.

Authors:  Arteiro Queiroz Menezes; Paulo Manuel Pêgo-Fernandes; Paulo Francisco Guerreiro Cardoso; Karina Andrighetti de Oliveira Braga; Natalia Aparecida Nepomuceno; Rogerio Pazetti; Aristides Tadeu Correia; Mauro Canzian; Jacqueline Klarosk Santim; Fabio Biscegli Jatene
Journal:  Clinics (Sao Paulo)       Date:  2012-11       Impact factor: 2.365

6.  Airway complications after lung transplantation: benefit of a conservative bronchoscopy strategy.

Authors:  Arnaud Patoir; Antoine Luchez; Olivier Tiffet; Paul Vercherin; Renaud Grima; François Tronc; François Philit; Jean-François Mornex; Jean-Michel Vergnon; Jean-Michel Maury
Journal:  J Thorac Dis       Date:  2020-05       Impact factor: 3.005

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.